Cyanotech (NASDAQ:CYAN) Given Coverage Optimism Rating of 0.22

News coverage about Cyanotech (NASDAQ:CYAN) has trended somewhat positive this week, according to Accern Sentiment Analysis. The research group identifies negative and positive news coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Cyanotech earned a media sentiment score of 0.22 on Accern’s scale. Accern also assigned news coverage about the biotechnology company an impact score of 47.7123799953135 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Shares of Cyanotech (CYAN) remained flat at $$4.10 on Thursday. The stock had a trading volume of 3,700 shares, compared to its average volume of 5,379. The firm has a market cap of $23.55, a PE ratio of 68.33 and a beta of 1.06. The company has a current ratio of 2.36, a quick ratio of 0.72 and a debt-to-equity ratio of 0.33. Cyanotech has a one year low of $3.25 and a one year high of $5.35.

Cyanotech (NASDAQ:CYAN) last issued its quarterly earnings data on Monday, November 6th. The biotechnology company reported $0.08 earnings per share (EPS) for the quarter. The business had revenue of $8.06 million for the quarter. Cyanotech had a return on equity of 2.06% and a net margin of 1.11%.

CYAN has been the topic of a number of recent research reports. TheStreet raised Cyanotech from a “d” rating to a “c-” rating in a research report on Monday, August 28th. ValuEngine cut Cyanotech from a “hold” rating to a “sell” rating in a research report on Friday, November 10th.

ILLEGAL ACTIVITY NOTICE: “Cyanotech (NASDAQ:CYAN) Given Coverage Optimism Rating of 0.22” was first published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark legislation. The original version of this news story can be viewed at https://ledgergazette.com/2017/12/14/cyanotech-cyan-getting-somewhat-favorable-news-coverage-report-shows-2.html.

About Cyanotech

Cyanotech Corporation is engaged in the production of natural products derived from microalgae for the nutritional supplements market. The Company’s products include Hawaiian Spirulina Pacifica and Hawaiian BioAstin. Hawaiian Spirulina Pacifica is a dietary supplement used for extra energy, a strengthened immune system, cardiovascular benefits and as a source of antioxidant carotenoids.

Insider Buying and Selling by Quarter for Cyanotech (NASDAQ:CYAN)

Receive News & Ratings for Cyanotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyanotech and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply